Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?

Journal of Parkinson's Disease

Volumn 6, Issue 1, 2016, Pages 39-51

  Oueslati, Abid ^a  

^a Université Laval   (Canada)

Author keywords

animal models; biomarker; cell based assays; degradation; kinases; membrane binding; Phosphorylation; subcellular localization; toxicity

Indexed keywords

ALPHA SYNUCLEIN; METAL ION; SERINE;

AMINO ACID SEQUENCE; CARBOXY TERMINAL SEQUENCE; CELLULAR DISTRIBUTION; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; HUMAN; MEMBRANE BINDING; NERVE CELL PLASTICITY; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SYNUCLEINOPATHY; ANIMAL; BRAIN; LEWY BODY; METABOLISM; PHOSPHORYLATION; SHY DRAGER SYNDROME;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; HUMANS; LEWY BODIES; LEWY BODY DISEASE; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; PHOSPHORYLATION;

EID: 84963780977     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-160779     Document Type: Review

References (129)

1. Lang AE, & LozanoAM(1998) Parkinson's disease. First of two parts. N Engl J Med, 339, 1044-1053.
2. Lang AE, & Lozano AM (1998) Parkinson's disease. Second of two parts. N Engl J Med, 339, 1130-1143.
3. McCann H, Stevens CH, Cartwright H, & Halliday GM (2014) alpha-Synucleinopathy phenotypes. Parkinsonism Relat Disord, 20(Suppl 1), S62-S67.
4. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, & Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett, 251, 205-208.
5. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, & Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A, 95, 6469-6473.
6. Lashuel HA, Overk CR, Oueslati A, & Masliah E (2013) The many faces of alpha-synuclein: From structure and toxicity to therapeutic target. Nat Rev Neurosci, 14, 38-48.
7. LeeVM,& Trojanowski JQ (2006) Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: New targets for drug discovery. Neuron, 52, 33-38.
8. Oueslati A, Fournier M, & Lashuel HA (2010) Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: Implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res, 183, 115-145.
9. Tenreiro S, Eckermann K, & Outeiro TF (2014) Protein phosphorylation in neurodegeneration: Friend or foe? Front Mol Neurosci, 7, 42.
10. Muntane G, Ferrer I, & Martinez-Vicente M (2012) alpha-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience, 200, 106-119.
11. Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM, Trojanowski JQ, Mann D, & Iwatsubo T (2002) Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem, 277, 49071-49076.
12. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, & Iwatsubo T (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol, 4, 160-164.
13. Kahle PJ, Neumann M, Ozmen L, & Haass C (2000) Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein. Ann N Y Acad Sci, 920, 33-41.
14. Okochi M,Walter J, Koyama A, Nakajo S, Baba M, Iwatsubo T, Meijer L, Kahle PJ,& Haass C (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem, 275, 390-397.
15. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, GaiWP,& Chilcote TJ (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem, 281, 29739-29752.
16. Takahashi M, Kanuka H, Fujiwara H, Koyama A, Hasegawa M, Miura M, & Iwatsubo T (2003) Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neurosci Lett, 336, 155-158.
17. Yamada M, Iwatsubo T, MizunoY,& MochizukiH(2004) Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: Resemblance to pathogenetic changes in Parkinson's disease. J Neurochem, 91, 451-461.
18. Chen L, & Feany MB (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci, 8, 657-663.
19. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, Odoy S, Fujiwara H, Hasegawa M, Iwatsubo T, Trojanowski JQ, Kretzschmar HA, & Haass C (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alphasynucleinopathies. J Clin Invest, 110, 1429-1439.
20. Bartels T, Choi JG, & Selkoe DJ (2011) alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature, 477, 107-110.
21. Fauvet B, Fares MB, Samuel F, Dikiy I, Tandon A, Eliezer D, & Lashuel HA (2012) Characterization of semisynthetic and naturally Nalpha-acetylated alpha-synuclein in vitro and in intact cells: Implications for aggregation and cellular properties of alpha-synuclein. J Biol Chem, 287, 28243-28262.
22. Dedmon MM, Lindorff-Larsen K, Christodoulou J, Vendruscolo M, & Dobson CM (2005) Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J Am Chem Soc, 127, 476-477.
23. Wu KP, Kim S, Fela DA, & Baum J (2008) Characterization of conformational and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: Implication for aggregation. J Mol Biol, 378, 1104-1115.
24. Burre J, Vivona S, Diao J, Sharma M, Brunger AT, & Sudhof TC (2013) Properties of native brain alpha-synuclein. Nature 498, E4-6; discussion E6-7.
25. Waudby CA, Camilloni C, Fitzpatrick AW, Cabrita LD, Dobson CM, Vendruscolo M, & Christodoulou J (2013) In-cell NMR characterization of the secondary structure populations of a disordered conformation of alphasynuclein within E. coli cells. PLoS One, 8, e72286.
26. Bertini I, Gupta YK, Luchinat C, Parigi G, Peana M, Sgheri L, & Yuan J (2007) Paramagnetism-based NMR restraints provide maximum allowed probabilities for the different conformations of partially independent protein domains. J Am Chem Soc, 129, 12786-12794.
27. Eliezer D, Kutluay E, Bussell R Jr, & Browne G (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol, 307, 1061-1073.
28. Del Mar C, Greenbaum EA, Mayne L, Englander SW, & Woods VL Jr (2005) Structure and properties of alphasynuclein and other amyloids determined at the amino acid level. Proc Natl Acad Sci U S A, 102, 15477-15482.
29. Cherny D, HoyerW, Subramaniam V, & Jovin TM (2004) Double-stranded DNA stimulates the fibrillation of alphasynuclein in vitro and is associated with the mature fibrils: An electron microscopy study. J Mol Biol, 344, 929-938.
30. Fernandez CO, Hoyer W, Zweckstetter M, Jares-Erijman EA, Subramaniam V, Griesinger C, & Jovin TM (2004) NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J, 23, 2039-2046.
31. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, & Lee VM (2003) Initiation and synergistic fibrillization of tau and alphasynuclein. Science, 300, 636-640.
32. Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, & Jakes R (1999) alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem, 274, 25481-25489.
33. Jensen PH, Islam K,Kenney J, Nielsen MS, Power J,& Gai WP (2000) Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments. J Biol Chem, 275, 21500-21507.
34. Yap TL, Gruschus JM, Velayati A, Westbroek W, Goldin E, Moaven N, Sidransky E, & Lee JC (2011) Alphasynuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem, 286, 28080-28088.
35. Brown DR (2007) Interactions between metals and alphasynuclein-function or artefact? FEBS J, 274, 3766-3774.
36. Paik SR, Shin HJ, Lee JH, Chang CS, & Kim J (1999) Copper(II)-induced self-oligomerization of alphasynuclein. Biochem J, 340(Pt 3), 821-828.
37. HoyerW, Cherny D, Subramaniam V, & Jovin TM (2004) Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry, 43, 16233-16242.
38. Schmid AW, Chiappe D, Pignat V, Grimminger V, Hang I, Moniatte M, & Lashuel HA (2009) Dissecting the mechanisms of tissue transglutaminase-induced cross-linking of alpha-synuclein: Implications for the pathogenesis of Parkinson disease. J Biol Chem, 284, 13128-13142.
39. Snead D, & Eliezer D (2014) Alpha-synuclein function and dysfunction on cellular membranes. Exp Neurobiol, 23, 292-313.
40. Dikiy I, & Eliezer D (2012) Folding and misfolding of alpha-synuclein on membranes. Biochim Biophys Acta, 1818, 1013-1018.
41. Pfefferkorn CM, Jiang Z, & Lee JC (2012) Biophysics of alpha-synuclein membrane interactions. Biochim Biophys Acta, 1818, 162-171.
42. Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, Fredenburg RA, Lansbury PT Jr, Fernandez CO, Eliezer D, Zweckstetter M, & Lashuel HA (2008) Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem, 283, 16895-16905.
43. Visanji NP, Wislet-Gendebien S, Oschipok LW, Zhang G, Aubert I, Fraser PE, & Tandon A (2011) Effect of Ser-129 phosphorylation on interaction of alpha-synuclein with synaptic and cellular membranes. J Biol Chem, 286, 35863-35873.
44. Pronin AN, Morris AJ, SurguchovA,& Benovic JL (2000) Synucleins are a novel class of substrates for G proteincoupled receptor kinases. J Biol Chem, 275, 26515-26522.
45. Nubling GS, Levin J, Bader B, Lorenzl S, Hillmer A, Hogen T, Kamp F, & Giese A (2014) Modelling Ser129 phosphorylation inhibits membrane binding of pore-forming alpha-synuclein oligomers. PLoS One, 9, e98906.
46. Fiske M, Valtierra S, Solvang K, Zorniak M, White M, Herrera S, Konnikova A, Brezinsky R, & Debburman S (2011) Contribution of Alanine-76 and Serine Phosphorylation in alpha-Synuclein Membrane Association and Aggregation in Yeasts. Parkinsons Dis, 2011, 392180.
47. Kuwahara T, Tonegawa R, Ito G, Mitani S, & Iwatsubo T (2012) Phosphorylation of alpha-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans. J Biol Chem, 287, 7098-7109.
48. Azeredo da Silveira S, Schneider BL, Cifuentes-Diaz C, Sage D, Abbas-Terki T, Iwatsubo T, Unser M,& Aebischer P (2009) Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum Mol Genet, 18, 872-887.
49. Hara S, Arawaka S, Sato H, Machiya Y, Cui C, Sasaki A, Koyama S, & Kato T (2013) Serine 129 phosphorylation of membrane-associated alpha-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner. Mol Biol Cell 24, 1649-1660, S1641-1643.
50. Hirai Y, Fujita SC, Iwatsubo T, & Hasegawa M (2004) Phosphorylated alpha-synuclein in normal mouse brain. FEBS Lett, 572, 227-232.
51. Bisaglia M, Tessari I, Mammi S, & Bubacco L (2009) Interaction between alpha-synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease. Neuromolecular Med, 11, 239-251.
52. Liu LL, & Franz KJ (2007) Phosphorylation-dependent metal binding by alpha-synuclein peptide fragments. J Biol Inorg Chem, 12, 234-247.
53. Lu Y, Prudent M, Fauvet B, Lashuel HA, & Girault HH (2011) Phosphorylation of alpha-Synuclein at Y125 and S129 alters its metal binding properties: Implications for understanding the role of alpha-Synuclein in the pathogenesis of Parkinson's Disease and related disorders. ACS Chem Neurosci, 2, 667-675.
54. Binolfi A, Rasia RM, Bertoncini CW, Ceolin M, ZweckstetterM, Griesinger C, JovinTM,& FernandezCO(2006) Interaction of alpha-synuclein with divalent metal ions reveals key differences: A link between structure, binding specificity and fibrillation enhancement. J Am Chem Soc, 128, 9893-9901.
55. Kostka M, Hogen T, Danzer KM, Levin J, Habeck M, Wirth A, Wagner R, Glabe CG, Finger S, Heinzelmann U, Garidel P, DuanW, Ross CA, Kretzschmar H, & Giese A (2008) Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J Biol Chem, 283, 10992-11003.
56. Hogen T, Levin J, Schmidt F, Caruana M, Vassallo N, Kretzschmar H, Botzel K, Kamp F, & Giese A (2012) Two different binding modes of alpha-synuclein to lipid vesicles depending on its aggregation state. Biophys J, 102, 1646-1655.
57. Levin J, Hogen T, Hillmer AS, Bader B, Schmidt F, Kamp F, Kretzschmar HA, Botzel K, & Giese A (2011) Generation of ferric iron links oxidative stress to alpha-synuclein oligomer formation. J Parkinsons Dis, 1, 205-216.
58. Rott R, Szargel R, Haskin J, Bandopadhyay R, Lees AJ, Shani V, & Engelender S (2011) alpha-Synuclein fate is determined by USP9X-regulated monoubiquitination. Proc Natl Acad Sci U S A, 108, 18666-18671.
59. Haj-Yahya M, Fauvet B, Herman-Bachinsky Y, Hejjaoui M, Bavikar SN, Karthikeyan SV, Ciechanover A, Lashuel HA, & Brik A (2013) Synthetic polyubiquitinated alpha-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology. Proc Natl Acad Sci U S A, 110, 17726-17731.
60. Tofaris GK, Kim HT, Hourez R, Jung JW, Kim KP, & Goldberg AL (2011) Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc Natl Acad Sci U S A, 108, 17004-17009.
61. Lonskaya I, Desforges NM, Hebron ML, & Moussa CE (2013) Ubiquitination increases parkin activity to promote autophagic alpha-synuclein clearance. PLoS One, 8, e83914.
62. Shahpasandzadeh H, Popova B, Kleinknecht A, Fraser PE, Outeiro TF, & Braus GH (2014) Interplay between sumoylation and phosphorylation for protection against alpha-synuclein inclusions. J Biol Chem, 289, 31224-31240.
63. Mahul-Mellier AL, Fauvet B, Gysbers A, Dikiy I, Oueslati A, Georgeon S, Lamontanara AJ, Bisquertt A, Eliezer D, Masliah E, Halliday G, Hantschel O, & Lashuel HA (2014) c-Abl phosphorylates alpha-synuclein and regulates its degradation: Implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. Hum Mol Genet, 23, 2858-2879.
64. Hebron ML, Lonskaya I, & Moussa CE (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models. Hum Mol Genet, 22, 3315-3328.
65. Chau KY, Ching HL, Schapira AH, & Cooper JM (2009) Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: Relevance to Parkinson's disease pathogenesis. J Neurochem, 110, 1005-1013.
66. Machiya Y, Hara S, Arawaka S, Fukushima S, Sato H, Sakamoto M,Koyama S,& Kato T (2010) Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J Biol Chem, 285, 40732-40744.
67. Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M, Olschewski D, Yin G, Zweckstetter M, Masliah E, Kahle PJ, Hirling H, & Lashuel HA (2010) Phosphorylation of synucleins by members of the Pololike kinase family. J Biol Chem, 285, 2807-2822.
68. Inglis KJ, Chereau D, Brigham EF, Chiou SS, Schobel S, Frigon NL, Yu M, Caccavello RJ, Nelson S, Motter R, Wright S, Chian D, Santiago P, Soriano F, Ramos C, Powell K, Goldstein JM, Babcock M,Yednock T, Bard F, Basi GS, Sham H, Chilcote TJ, McConlogue L, Griswold-Prenner I, & Anderson JP (2009) Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem, 284, 2598-2602.
69. Bergeron M, Motter R, Tanaka P, Fauss D, Babcock M, Chiou SS, Nelson S, San Pablo F,& Anderson JP (2014) In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 alpha-synuclein phosphorylation in mouse brain. Neuroscience, 256, 72-82.
70. Oueslati A, Schneider BL, Aebischer P, & Lashuel HA (2013) Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. Proc Natl Acad Sci U S A, 110, E3945-E3954.
71. Tenreiro S, Reimao-Pinto MM, Antas P, Rino J,Wawrzycka D, Macedo D, Rosado-Ramos R, Amen T, Waiss M, Magalhaes F, Gomes A, Santos CN, Kaganovich D,& Outeiro TF (2014) Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease. PLoS Genet, 10, e1004302.
72. Seeburg DP, Pak D, & Sheng M (2005) Polo-like kinases in the nervous system. Oncogene, 24, 292-298.
73. SeeburgDP, Feliu-Mojer M, Gaiottino J, PakDT,& Sheng M (2008) Critical role of CDK5 and Polo-like kinase 2 in homeostatic synaptic plasticity during elevated activity. Neuron, 58, 571-583.
74. Burre J (2015) The Synaptic Function of alpha-Synuclein. J Parkinsons Dis, 5(4), 699-713.
75. Matsumoto T, Wang PY, Ma W, Sung HJ, Matoba S, & Hwang PM (2009) Polo-like kinases mediate cell survival in mitochondrial dysfunction. Proc Natl Acad Sci U S A, 106, 14542-14546.
76. Li J, Ma W, Wang PY, Hurley PJ, Bunz F, & Hwang PM (2014) Polo-like kinase 2 activates an antioxidant pathway to promote the survival of cells with mitochondrial dysfunction. Free Radic Biol Med, 73, 270-277.
77. Hashimoto M, Hsu LJ, Rockenstein E, Takenouchi T, Mallory M, & Masliah E (2002) alpha-Synuclein protects against oxidative stress via inactivation of the c-Jun Nterminal kinase stress-signaling pathway in neuronal cells. J Biol Chem, 277, 11465-11472.
78. McFarland MA, Ellis CE, Markey SP, & Nussbaum RL (2008) Proteomics analysis identifies phosphorylationdependent alpha-synuclein protein interactions. Mol Cell Proteomics, 7, 2123-2137.
79. Yin G, Lopes da Fonseca T, Eisbach SE, Anduaga AM, Breda C, Orcellet ML, Szego EM, Guerreiro P, Lazaro DF, Braus GH, Fernandez CO, Griesinger C, Becker S, Goody RS, Itzen A, Giorgini F, Outeiro TF, & Zweckstetter M (2014) alpha-Synuclein interacts with the switch region of Rab8a in a Ser129 phosphorylation-dependent manner. Neurobiol Dis, 70, 149-161.
80. Burre J, Sharma M, TsetsenisT, BuchmanV, EthertonMR, & Sudhof TC (2010) Alpha-synuclein promotes SNAREcomplex assembly in vivo and in vitro. Science, 329, 1663-1667.
81. Burre J, Sharma M, & Sudhof TC (2012) Systematic mutagenesis of alpha-synuclein reveals distinct sequence requirements for physiological and pathological activities. J Neurosci, 32, 15227-15242.
82. Payton JE, Perrin RJ, Clayton DF, & George JM (2001) Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells. Brain Res Mol Brain Res, 95, 138-145.
83. Zhou RM, Huang YX, Li XL, Chen C, Shi Q, Wang GR, Tian C, Wang ZY, Jing YY, Gao C, & Dong XP (2010) Molecular interaction of alpha-synuclein with tubulin influences on the polymerization of microtubule in vitro and structure of microtubule in cells. Mol Biol Rep, 37, 3183-3192.
84. Monti B, Polazzi E, Batti L, Crochemore C, Virgili M, & Contestabile A (2007) Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death. J Neurochem, 103, 518-530.
85. Goncalves S, & Outeiro TF (2013) Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy. Mol Neurobiol, 47, 1081-1092.
86. Ma KL, Song LK, Yuan YH, Zhang Y, Han N, Gao K, & Chen NH (2014) The nuclear accumulation of alphasynuclein is mediated by importin alpha and promotes neurotoxicity by accelerating the cell cycle. Neuropharmacology, 82, 132-142.
87. Lee BR, Matsuo Y, Cashikar AG, & Kamitani T (2013) Role of Ser129 phosphorylation of alpha-synuclein in melanoma cells. J Cell Sci, 126, 696-704.
88. McLean PJ, Ribich S, & Hyman BT (2000) Subcellular localization of alpha-synuclein in primary neuronal cultures: Effect of missense mutations. J Neural Transm Suppl, 53-63.
89. Seo JH, Rah JC, Choi SH, Shin JK, Min K, Kim HS, Park CH, Kim S, Kim EM, Lee SH, Lee S, Suh SW, & Suh YH (2002) Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J, 16, 1826-1828.
90. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, & Mucke L (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science, 287, 1265-1269.
91. Wakamatsu M, Ishii A, Ukai Y, Sakagami J, Iwata S, Ono M, Matsumoto K, Nakamura A, Tada N, Kobayashi K, Iwatsubo T, & Yoshimoto M (2007) Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. J Neurosci Res, 85, 1819-1825.
92. Amschl D, Neddens J, Havas D, Flunkert S, Rabl R, Romer H, Rockenstein E, Masliah E, Windisch M, & Hutter-PaierB(2013) Time course and progression of wild type alpha-synuclein accumulation in a transgenic mouse model. BMC Neurosci, 14, 6.
93. Schell H, Hasegawa T, Neumann M, & Kahle PJ (2009) Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Neuroscience, 160, 796-804.
94. Goers J, Manning-Bog AB, McCormack AL, Millett IS, Doniach S, Di MonteDA,Uversky VN,& Fink AL (2003) Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry, 42, 8465-8471.
95. Yu S, Li X, Liu G, Han J, Zhang C, Li Y, Xu S, Liu C, Gao Y, Yang H, Ueda K, & Chan P (2007) Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody. Neuroscience, 145, 539-555.
96. Huang Z, Xu Z, Wu Y, & Zhou Y (2011) Determining nuclear localization of alpha-synuclein in mouse brains. Neuroscience, 199, 318-332.
97. Fares MB, Ait-Bouziad N, Dikiy I, Mbefo MK, Jovicic A, Kiely A, Holton JL, Lee SJ, Gitler AD, Eliezer D, & Lashuel HA (2014) The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of alpha-synuclein, and enhances its secretion and nuclear localization in cells.HumMol Genet, 23, 4491-4509.
98. Mbefo MK, Fares MB, Paleologou K, Oueslati A, Yin G, Tenreiro S, Pinto M, Outeiro T, Zweckstetter M, Masliah E, & Lashuel HA (2015) Parkinson disease mutant E46K enhances alpha-synuclein phosphorylation in mammalian cell lines, in yeast, and in vivo. J Biol Chem, 290, 9412-9427.
99. McCormack AL, Mak SK, & Di Monte DA (2012) Increased alpha-synuclein phosphorylation and nitration in the aging primate substantia nigra. Cell Death Dis, 3, e315.
100. Canron MH, Perret M, Vital A, Bezard E, & Dehay B (2012) Age-dependent alpha-synuclein aggregation in the Microcebus murinus lemur primate. Sci Rep, 2, 910.
101. McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, & McLean PJ (2009) Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol, 68, 515-524.
102. Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, Mandel RJ, & Muzyczka N (2008) The phosphorylation state of Ser-129 in human alphasynuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad SciUSA, 105, 763-768.
103. Febbraro F, Sahin G, Farran A, Soares S, Jensen PH, Kirik D, & Romero-Ramos M (2013) Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease. Neurobiol Dis, 56, 47-58.
104. Qing H,WongW, McGeer EG,& McGeerPL(2009) Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun, 387, 149-152.
105. Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S,& Kato T (2011) Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci, 31, 16884-16894.
106. Salvi M, Trashi E, Marin O, Negro A, Sarno S,& PinnaLA (2012) Superiority of PLK-2 as alpha-synuclein phosphorylating agent relies on unique specificity determinants. Biochem Biophys Res Commun, 418, 156-160.
107. Luk KC, Song C, O'Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, & Lee VM (2009) Exogenous alpha-synuclein fibrils seed the formation of Lewy bodylike intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A, 106, 20051-20056.
108. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, & Lee VM (2011) Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron, 72, 57-71.
109. Oueslati A, Ximerakis M, & Vekrellis K (2014) Protein Transmission, Seeding and Degradation: Key Steps for alpha-Synuclein Prion-Like Propagation. Exp Neurobiol, 23, 324-336.
110. Walker DG, Lue LF, Adler CH, Shill HA, Caviness JN, Sabbagh MN, Akiyama H, Serrano GE, Sue LI, Beach TG, & Arizona Parkinson Disease C (2013) Changes in properties of serine 129 phosphorylated alpha-synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol, 240, 190-204.
111. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL, 3rd, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG, & Arizona Parkinson's Disease C (2009) Unified staging system for Lewy body disorders: Correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol, 117, 613-634.
112. Zhou J, Broe M, Huang Y, Anderson JP, Gai WP, Milward EA, PorrittM,Howells D, Hughes AJ,Wang X,& Halliday GM (2011) Changes in the solubility and phosphorylation of alpha-synuclein over the course of Parkinson's disease. Acta Neuropathol, 121, 695-704.
113. Ryu MY, Kim DW, Arima K, Mouradian MM, Kim SU, & Lee G (2008) Localization of CKII beta subunits in Lewy bodies of Parkinson's disease. J Neurol Sci, 266, 9-12.
114. Arawaka S, Wada M, Goto S, Karube H, Sakamoto M, Ren CH, Koyama S, Nagasawa H, Kimura H, Kawanami T, Kurita K, Tajima K, Daimon M, Baba M, Kido T, Saino S, Goto K, Asao H, Kitanaka C, Takashita E, Hongo S, Nakamura T, Kayama T, Suzuki Y, Kobayashi K, Katagiri T, Kurokawa K, Kurimura M, Toyoshima I, Niizato K, Tsuchiya K, Iwatsubo T, Muramatsu M, Matsumine H, & Kato T (2006) The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease. J Neurosci, 26, 9227-9238.
115. Qing H, Zhang Y, Deng Y, McGeer EG, & McGeer PL (2009) Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Biochem Biophys Res Commun, 390, 1229-1234.
116. Waxman EA, & Giasson BI (2011) Characterization of kinases involved in the phosphorylation of aggregated alpha-synuclein. J Neurosci Res, 89, 231-247.
117. Oueslati A, Paleologou KE, Schneider BL, Aebischer P,& Lashuel HA (2012) Mimicking phosphorylation at serine 87 inhibits the aggregation of human alpha-synuclein and protects against its toxicity in a rat model of Parkinson's disease. J Neurosci, 32, 1536-1544.
118. Foulds PG, Mitchell JD, Parker A, Turner R, Green G, Diggle P, Hasegawa M, Taylor M, Mann D, & Allsop D (2011) Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J, 25, 4127-4137.
119. Foulds PG, Diggle P, Mitchell JD, Parker A, Hasegawa M, Masuda-Suzukake M, Mann DM, & Allsop D (2013) A longitudinal study on alpha-synuclein in blood plasma as a biomarker for Parkinson's disease. Sci Rep, 3, 2540.
120. Doppler K, Ebert S, Uceyler N, Trenkwalder C, Ebentheuer J, Volkmann J, & Sommer C (2014) Cutaneous neuropathy in Parkinson's disease: A window into brain pathology. Acta Neuropathol, 128, 99-109.
121. Donadio V, Incensi A, Leta V, Giannoccaro MP, Scaglione C, Martinelli P, Capellari S, Avoni P, Baruzzi A, & Liguori R (2014) Skin nerve alpha-synuclein deposits: A biomarker for idiopathic Parkinson disease. Neurology, 82, 1362-1369.
122. Pouclet H, Lebouvier T, Coron E, Neunlist M, & Derkinderen P (2012) Lewy pathology in gastric and duodenal biopsies in Parkinson's Disease. Mov Disor, 27, 708.
123. Hilton D, StephensM,Kirk L,Edwards P, Potter R, Zajicek J, Broughton E, Hagan H, & Carroll C (2014) Accumulation of alpha-synuclein in the bowel of patients in the pre-clinical phase of Parkinson's disease. Acta Neuropathol, 127, 235-241.
124. Swirski M, Miners JS, de Silva R, Lashley T, Ling H, Holton J, Revesz T, & Love S (2014) Evaluating the relationship between amyloid-beta and alpha-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease. Alzheimers Res Ther, 6, 77.
125. Foulds PG, Yokota O, Thurston A, Davidson Y, Ahmed Z, Holton J, Thompson JC, Akiyama H, Arai T, Hasegawa M, Gerhard A, Allsop D, & Mann DM (2012) Post mortem cerebrospinal fluid alpha-synuclein levels are raised in multiple system atrophy and distinguish this from the other alpha-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiol Dis, 45, 188-195.
126. Lou H, Montoya SE, Alerte TN, Wang J, Wu J, Peng X, Hong CS, Friedrich EE, Mader SA, Pedersen CJ, Marcus BS, McCormack AL, Di Monte DA, Daubner SC,& Perez RG (2010) Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem, 285, 17648-17661.
127. Kosten J, Binolfi A, Stuiver M, Verzini S, Theillet FX, Bekei B, van Rossum M, & Selenko P (2014) Efficient modification of alpha-synuclein serine 129 by protein kinase CK1 requires phosphorylation of tyrosine 125 as a priming event. ACS Chem Neurosci, 5, 1203-1208.
128. Chen L, Periquet M, Wang X, Negro A, McLean PJ, Hyman BT, & Feany MB (2009) Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest, 119, 3257-3265.
129. Ulmer TS, Bax A, Cole NB, & Nussbaum RL (2005) Structure and dynamics of micelle-bound human alphasynuclein. J Biol Chem, 280, 9595-9603.